Hansa Biopharma AB (HNSAN) Stock Statistics & Valuation Metrics

Hansa Biopharma AB has a market cap or net worth of $7.22B. The enterprise value is $4.01K.

Hansa Biopharma AB has 101,763,220 shares outstanding. The number of shares has decreased by -2.65% in one year.

Hansa Biopharma AB’s return on equity (ROE) is 6.00 and return on invested capital (ROIC) is -57.78%.

The current PE Ratio of Hansa Biopharma AB is ―. Hansa Biopharma AB’s PEG ratio is 0.11.

In the last 12 months, Hansa Biopharma AB had revenue of 222.26M and earned -534.11M in profits. Earnings per share was -6.52.

In the last 12 months, operating cash flow was -527.70M and capital expenditures -18.54M, giving a free cash flow of -546.24M billion.

Hansa Biopharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

Hansa Biopharma AB upcoming earnings date is Nov 5, 2026, Before Open (Confirmed).

Hansa Biopharma AB as a current ratio of 1.94, with Debt / Equity ratio of -198.72%

In the past 12 months, Hansa Biopharma AB has paid 2.27M in taxes.

Hansa Biopharma AB EV to EBITDA ratio is -6.25, with an EV/FCF ratio of -5.50.

Hansa Biopharma AB has $552.81M in cash and marketable securities with $1.03B in debt, giving a net cash position of -$480.99M billion.

Gross margin is 57.32%, with operating margin of -234.27%, and net profit margin of -240.30%.

The average price target for Hansa Biopharma AB is $185.03, which is 11.43% higher than the current price. The consensus rating is Moderate Buy